/
•
•
Detailed stories on technology startups, business and economic current affairs.
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.

Over the past four decades, Hyderabad-based Dr. Reddy’s Laboratories has earned phenomenal success in the global market. The drugmaker was the eighth largest generics player in the US as of 31 March 2024, sitting snugly with the likes of Sun Pharmaceutical Industries, Cipla and Lupin. Things on the home turf haven’t been as exciting though, with the company ranking 10th in terms of revenue. But that’s about to change.
Dr Reddy’s is now gunning for the fifth spot in the league table. Not just that. It wants to get there in just five years. “India remains a strategic priority for …